NICE signs agreement with Colombia’s Institute of Health Technology Assessment to forge closer working ties
Research and knowledge sharing key to collaborative working approach agreed the two agencies
-
Innovation through HTA: theme for HTAi 2021 Annual Meeting announced
Health Technology Assessment International (HTAi) has announced the theme for the 2021 Annual Meeting which will be held from 19-23 June in Manchester.
-
Cancer patients to benefit from new histology independent treatment
Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF).
-
NICE draft guidance does not recommend siponimod for treating secondary progressive multiple sclerosis
NICE has today (25 June 2020) issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
